Business and Finance

A cohort study investigates how the use of a murine chimeric monoclonal antibody biosimilar—as opposed to the original biological drug—affects healthcare expenditures.

IQVIA report explores the latest spending tendencies in the United States, while providing additional clarity as to why COVID-19 vaccines and therapeutics continue to experience a decline in volume.

The acquisition, the parties say, will benefit pharma and biotech in the clinical and commercial stages.

Collaboration will be oncology based—centered around allogeneic CAR-T cell therapy product candidates—and will provide Poseida with up to $550 million if certain milestones are met.

Per the US strategic partnership agreement, the adalimumab high-concentration interchangeable biosimilar will be distributed under the Quallent Pharmaceuticals private label.

Study explores how the Inflation Reduction Act’s Drug Price Negotiation Program and its maximum fair prices impact incentives for investments in post-approval activity.

The merger exponentially grows ONO’s oncology pipeline.

The complex will research solutions for manufacturing antibodies, mRNA applications, and more.

The company adds a top-10 CDMO to its portfolio in the process, while also expanding its commitment to the pharma industry.

The deal further grows the Big Pharma company’s US production capabilities, especially when it comes to global parenteral products.

Deal gives Incyte access to Escient’s pipeline of oral MRGPR antagonists, including EP262 and EP547.

Company also purchased equipment for 12 good manufacturing practice clean rooms.

Capital also expected to assist the advancement of Evergreen's radiopharmaceutical discovery pipeline into clinical trials.

Cohort study examines the potential for spending to significantly decrease for individuals who use these generic versions of biologics.

Analysis determines the suggested value of medications for diabetes if they were closer to production costs.

A breakdown of the issues surrounding retail pharmacy—and what can be done to address these difficulties in a timely manner.

Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.

A study investigates how a New Mexico law can impact patients’ out-of-pocket costs surrounding mental health and substance use disorder medications.

The purpose for the deal, the CDMO says, is to meet the demand for commercial mammalian contract manufacturing.

Conference’s opening session addresses the evolving landscape of healthcare coverage and accessibility.

This financial toxicity is quite prominent, but what can be done to remedy treatment costs?

With out-of-pocket healthcare costs resulting in financial issues for patients, a cross-sectional study closely examines whether they are linked to more premature deaths.

A proposed Senate bill is intended to protect citizens’ private health and genetic information.

The contributions consist of multiple investments that aim to boost pandemic preparedness and overall public health protection.

Momentum from the previous two years will propel the sector into the rest of 2024, says AM Best analysis.